As the vast majority of countries all over the world have decided to open up for international travelers, most of them still keep in place measures depending on the type of vaccine travelers have been immunized with.

Currently, all countries recognize proof of vaccination with one of the vaccines approved by the European Medicines Agency (EMA), which are Pfizer/BioNTech, Moderna, AstraZeneca, and Johnson and Johnson. However, the case is not the same with other vaccines, such as Sinovac, VisaGuide.World reports.

Consequently, when traveling to a country, one should not forget to check the validity of their vaccine.

VisaGuide.World has developed such a tool that enables you to check whether the destination you plan to visit recognizes as valid proof of immunization the vaccine you have been jabbed with.

The following countries allow entry for persons vaccinated with the Sinovac vaccine:

AlbaniaFinlandParaguay
ArmeniaGeorgiaPhilippines
AustriaGreeceSerbia
AzerbaijanHong KongSouth Africa
BangladeshIcelandSpain
BrazilIndonesiaSri Lanka
CambodiaKazakhstanSweden
Cape VerdeKyrgyzstanSwitzerland
ChileLaosTajikistan
ChinaMacedoniaThailand
ColombiaMalaysiaTogo
CyprusMexicoTunisia
Dominican RepublicNepalTurkey
East TimorNetherlandsUkraine
EcuadorOmanUruguay
EgyptPakistanZimbabwe
El SalvadorPanama

Sinovac is a vaccine manufactured by a Beijing-based pharmaceutical company, and the same is part of the World Health Organization (WHO) Emergency Listing.

WHO validated the Sinovac-CoronaVac vaccine for emergency use back on June 1 this year and assured countries, funders, and communities that the vaccine meets international standards for efficacy, safety, and manufacturing.

“In the case of the Sinovac-CoronaVac vaccine, the WHO assessment included on-site inspections of the production facility. The Sinovac-CoronaVac product is an inactivated vaccine. Its easy storage requirements make it very manageable and particularly suitable for low-resource settings,” the WHO’s statement regarding the Sinovac vaccine reads.

The emergency approval of Sinovac came after the directors of WHO, the International Monetary Fund, the World Bank, and the World Trade Organisation appealed for an investment fund of €42 billion to help end the pandemic and restore free movement.

All of the contributors have called for the designated amount to be distributed fairly and be invested in vaccine production, oxygen supplies, and COVID-19 treatments.

Following its approval, WHO said that the vaccine prevented symptomatic disease in 51 percent of persons who have been vaccinated against the Coronavirus disease as well as prevented hospitalization and symptoms in 100 percent of samples.

In addition, since the vaccine was approved for emergency use, the jab was added to the COVAX program, which aims to allow international fair access to the vaccines.

It has been anticipated that the listing of the vaccine for emergency use will help the COVAX initiative, which has been severely struggling with supply issues.

“The world desperately needs multiple Covid-19 vaccines to address the huge access inequity across the globe. We urge manufacturers to participate in the COVAX facility, share their know-how and data, and contribute to bringing the pandemic under control,” WHO’s assistant director-general for access to health products, Mariangela Simao, said.

Sinovac vaccine, which now is already used in tens of countries, is recommended for all persons over the age of 18 and is recommended that everyone takes the second dose two to four weeks after the first one.